Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model

Follicular lymphomas (FLs) account for 35–40% of all adult lymphomas. Treatment typically involves chemotherapy combined with the anti-CD20 monoclonal antibody (MAb) rituximab (RTX). The development of the type II anti-CD20 MAb obinutuzumab (GA101) aims to further improve treatment. Here, using FL c...

Descripción completa

Detalles Bibliográficos
Autores principales: Decaup, E, Jean, C, Laurent, C, Gravelle, P, Fruchon, S, Capilla, F, Marrot, A, Al Saati, T, Frenois, F-X, Laurent, G, Klein, C, Varoqueaux, N, Savina, A, Fournié, J-J, Bezombes, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763386/
https://www.ncbi.nlm.nih.gov/pubmed/23933705
http://dx.doi.org/10.1038/bcj.2013.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763386/
https://www.ncbi.nlm.nih.gov/pubmed/23933705
http://dx.doi.org/10.1038/bcj.2013.32

Ejemplares similares